Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFanyue Meng, Fengcai Zhu, Siyue Jia et al.|Signal Transduction and Targeted Therapy|2021Cited by 36